NCT03014804 (disregard the references to a "lung tumor" vaccine. This is a GBM trial and those references were a mistake which should be fixed soon.
Another trial will soon be opening for newly diagnosed GBM testing the Agenus Prophage vaccine (HSPPC-96) in combination with pembrolizumab. This is a randomized phase 2 trial and unfortunately one arm will be treated with standard of care + pembrolizumab + placebo, while the other arm gets standard + pembrolizumab + vaccine.
Another trial of HSPPC-96 for newly diagnosed GBM reported some results at ASCO 2015. Patients with high PD-L1 expression had median survival of 18 months, while patients with low PD-L1 expression had an amazing median survival of 44.7 months. There is thus very good rationale to combine this vaccine with a PD-1 inhibitor such as pembrolizumab.